Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue
Product sales	$ 734,502	$ 947,219
Laboratory services	16,105	129,420
Collaboration revenue	21,164	0
Total revenue	771,771	1,076,639
Operating expenses
Cost of products sold	424,950	345,967
Cost of services	100,233	315,709
Research and development	2,122,515	1,953,429
General and administrative	1,969,216	1,538,046
Sales and marketing	1,105,586	1,399,435
Total operating expenses	5,722,500	5,552,586
Operating loss	(4,950,729)	(4,475,947)
Other expense
Interest and other income	21	173
Interest expense	(29,844)	(41,734)
Foreign currency transaction gains	2,620	11,328
Total other expense	(27,203)	(30,233)
Loss before income taxes	(4,977,932)	(4,506,180)
Provision for income taxes	0	0
Net loss	(4,977,932)	(4,506,180)
Preferred stock dividends and beneficial conversion	0	0
Net loss available to common stockholders	$ (4,977,932)	$ (4,506,180)
Net loss per common share - basic and diluted	$ (0.19)	$ (0.36)
Weighted average shares outstanding - basic and diluted	26,079,461	12,568,941
Net loss	$ (4,977,932)	$ (4,506,180)
Other comprehensive loss - foreign currency translation	(3,757)	(1,112)
Comprehensive loss	$ (4,981,689)	$ (4,507,292)